Gibson Dunn announced that Margaux J. Hall has joined the firm as a partner in its FDA and Health Care and Life Sciences Practice Groups in Washington, D.C.
Hall advises pharmaceutical manufacturers, investors, and other entities in the supply chain on drug pricing, market access, and value-based arrangements.
Her practice focuses on legal and policy changes affecting pricing, reimbursement, coverage, and access to drugs, vaccines, and devices. She also provides health regulatory counsel on mergers and other transactions, government enforcement matters, and litigation.
Gibson Dunn said Hall’s arrival strengthens its FDA and health care platform as pricing and reimbursement issues increasingly influence transactions, commercialization strategies, and investment decisions across the life sciences industry.
The firm also noted that the regulatory and enforcement landscape around drug pricing has become more aggressive, with federal and state authorities increasing scrutiny of the pharmaceutical and biotech sectors.
Before joining Gibson Dunn, Hall was a partner at an international law firm. She has also pursued a Fulbright Program fellowship focused on health care law and health system reform in South Africa and led similar research programs at the World Bank Group.
Gibson Dunn’s FDA and Health Care Practice Group advises clients on legal issues involving regulated products and health care services. The group includes more than 80 lawyers across 12 offices worldwide.
KEY QUOTES:
“Margaux is a go-to advisor to clients across the pharmaceutical supply chain on drug pricing and market access issues, and her arrival further strengthens our premier FDA and health care platform. As pricing and reimbursement issues increasingly influence transactions, commercialization strategy, and investment decisions across the life sciences industry, her specialized expertise—combined with our deep bench across regulatory, transactional, white collar, and litigation disciplines—positions us to advise clients on their most consequential matters.”
Jonathan M. Phillips, Co-Chair of the FDA and Health Care Practice Group at Gibson Dunn
“The regulatory and enforcement landscape surrounding drug pricing has become more aggressive, with federal and state authorities increasing their scrutiny of industry. Margaux has been at the forefront of these developments, and her experience enhances our ability to help pharmaceutical and biotech clients manage high-stakes investigations, enforcement actions, and related litigation.”
Gus Eyler, Co-Chair of the FDA and Health Care and Consumer Protection Practice Groups at Gibson Dunn
“Gibson Dunn’s unmatched platform across regulatory, litigation, investigations, and transactional practices creates an exceptionally strong foundation for advising clients on today’s pricing and market access challenges. I’m excited to join a team with the breadth, sophistication, and collaborative culture to help life sciences clients navigate one of the industry’s most dynamic and rapidly evolving areas.”
Margaux J. Hall
